REGN Q2 2020 Earnings — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

REGNRegeneron Pharmaceuticals, Inc.

$81B

Q2 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2.0B+23.7% YoY

Gross Profit

$1.6B82.9% margin

Operating Income

$656M33.6% margin

Net Income

$897M46.0% margin

EPS (Diluted)

$7.61

QoQ Revenue Growth

+6.8%

Cash Flow

Operating Cash Flow

$943M

Free Cash Flow

$814M

Stock-Based Comp.

$104M

Balance Sheet

Total Assets

$14.4B

Total Liabilities

$5.4B

Stockholders' Equity

$9.1B

Cash & Equivalents

$2.0B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2.0B	$1.6B	+23.7%
Gross Profit	$1.6B	$1.4B	+17.2%
Operating Income	$656M	$316M	+108.0%
Net Income	$897M	$193M	+364.7%

Revenue Segments

Product

$1.2B100%